After correlating expression scores with classical stromal genes and with other key stromal markers (such as CAV1, TAGLN, and VIM), CD3 and CD4 markers and basal activity, the researchers concluded that the top 10% of stromal expression was associated with high genomic risk scores (Decipher ≥ 0.6), high Cancer of the Prostate Risk Assessment-Postsurgical (CAPRA-S) scores, Gleason 9 to 10 disease, and an increased risk for metastasis (hazard ratio, 2.35; 95% CI, 1.37–4.02; p = 0.001). This evidence concerns the gene VIM and cancer.